Skip to main content

CareDx Inc

For the period ended Sep 30, 2024. Filed Nov 4, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 4, 2024

CDNA$80.77-4.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows for the and

Condensed Consolidated Statements of Cash Flows

Nine Months Ended September 30,
20242023
Operating activities:
Net loss$(25,461)$(72,187)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation40,20839,125
Depreciation and amortization10,83310,755
Asset impairments and write-downs—1,000
Amortization of right-of-use assets4,2364,020
Unrealized loss on long-term marketable equity securities—1,185
Revaluation of contingent consideration to estimated fair value7611,731
Loss on disposal of asset—37
Gain on settlement of obligation and recovery of written-off investment—(2,109)
Amortization of premium and accretion of discount on short-term marketable securities, net1,177(3,410)
Revaluation of common stock warrant liability to estimated fair value—(10)
Changes in operating assets and liabilities:
Accounts receivable(15,550)15,351
Inventory294758
Prepaid and other assets(315)2,542
Operating lease liabilities, net(4,425)(4,088)
Accounts payable(6,699)(990)
Accrued compensation10,239(336)
Accrued and other liabilities804(3,462)
Change in deferred taxes5781
Net cash provided by (used in) operating activities16,159(10,007)
Investing activities:
Acquisitions of business, net of cash acquired—(6,682)
Acquisitions of intangible assets—(896)
Purchases of short-term marketable securities(143,185)(192,131)
Maturities of short-term marketable securities149,775206,503
Purchase of corporate equity securities—(965)
Additions of capital expenditures(4,962)(6,750)
Net cash provided by (used in) investing activities1,628(921)
Financing activities:
Proceeds from issuance of common stock under employee stock purchase plan1,3971,495
Taxes paid related to net share settlement of restricted stock units(6,525)(2,514)
Proceeds from exercise of warrants—4
Proceeds from exercise of stock options3,322107
Payment of contingent consideration on acquisitions(2,375)(250)
Repurchase and retirement of common stock(522)(1,571)
Net cash used in financing activities(4,703)(2,729)
Effect of exchange rate changes on cash and cash equivalents125(224)
Net increase (decrease) in cash, cash equivalents and restricted cash13,209(13,881)
Cash, cash equivalents and restricted cash at beginning of period82,78390,443
Cash, cash equivalents and restricted cash at end of period$95,992$76,562
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.